(Circulation. 1999;99:1022-1026.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Pediatric Cardiology (B.L.S.), Boston Children's Hospital, Boston, Mass; Department of Genetics and Howard Hughes Medical Institute (H.N., J.G.S.), Harvard Medical School, Boston, Mass; and Cardiovascular Division and Howard Hughes Medical Institute (J.A.O., D.F., C.M., S.S., D.W.B., C.E.S.), Brigham and Women's Hospital, Boston, Mass.
Correspondence to Christine E. Seidman, MD, Department of Genetics, Alpert Room 533, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115. E-mail cseidman{at}rascal.med.harvard.edu
| Abstract |
|---|
|
|
|---|
Methods and ResultsWe clinically evaluated 3 generations of a
kindred with autosomal dominant transmission of dilated
cardiomyopathy. Nine surviving and affected
individuals had early-onset disease (ventricular chamber
dilation during the teenage years and congestive heart failure during
the third decade of life). The disease was nonpenetrant in 2 obligate
carriers. To identify the causal gene defect, linkage studies were
performed. A new dilated cardiomyopathy locus was
identified on chromosome 2 between loci GCG and
D2S72 (maximum logarithm of odds [LOD]
score=4.86 at
=0). Because the massive gene encoding titin, a
cytoskeletal muscle protein, resides in this disease interval,
sequences encoding 900 amino acid residues of the cardiac-specific
(N2-B) domain were analyzed. Five sequence variants were
identified, but none segregated with disease in this family.
ConclusionsA dilated cardiomyopathy locus (designated CMD1G) is located on chromosome 2q31 and causes early-onset congestive heart failure. Although titin remains an intriguing candidate gene for this disorder, a disease-causing mutation is not present in its cardiac-specific N2-B domain.
Key Words: cardiomyopathy genetics mapping
| Introduction |
|---|
|
|
|---|
35% of cases.3 Familial dilated cardiomyopathy exhibits significant genetic and clinical heterogeneity. This disorder can be transmitted as an autosomal dominant or a recessive, matrilinear (mitochondrial), or X-linked trait; dominant inheritance occurs most frequently. Six different dominant disease loci have been identified.4 5 6 7 8 9 CMD1A on chromosome 14 and CMD1E on chromosome 35 cause dilated cardiomyopathy and conduction system disease. CMD1F, on chromosome 6, causes dilated cardiomyopathy and adult-onset limb girdle dystrophy.6 Isolated dilated cardiomyopathy is caused by mutations in cardiac actin10 and unknown gene mutations encoded at loci CMD1B (chromosome 1q327 ), CMD1C (chromosome 98 ), and CMD1D (chromosome 10q219 ).
We report a new dilated cardiomyopathy locus on chromosome 2q31 (designated CMD1G) that causes dominant transmission of early-onset disease. This genomic location implicated titin as a candidate disease gene; however, no mutation was identified in sequences encoding the cardiac-specific domain of this massive cytoskeletal muscle protein.
| Methods |
|---|
|
|
|---|
Genetic Studies
Genetic analyses were performed with DNA samples
extracted from whole blood or Epstein-Barr virustransformed
lymphocytes, as described previously.13 Linkage studies
used short tandem repeat markers (STRs) spaced
10 cM apart, with a
polymorphic content of >0.70.
Polymerase chain reaction (PCR) amplification of genomic DNA with selected STR primers was performed in a 10-µL reaction containing 100 ng genomic DNA; 40 ng polynucleotide kinase 32P-labeled oligonucleotide primer; 40 ng reverse complement primer; a 200 mmol/L concentration each of dATP, dCTP, dGTP, and dTTP; Taq polymerase; and commercial buffer (Boehringer Mannheim). Thirty cycles of PCR amplification were performed with the following conditions: denaturing at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 40 seconds. PCR products were resolved on 6% denaturing polyacrylamide gels (BioRad) and visualized with the use of autoradiography. Genotypes were determined without knowledge of the patient's clinical status.
Linkage Analysis
Two-point logarithm of odds (LOD) scores were calculated using
the program MLINK (version 5.1), and multipoint LOD scores were
calculated using the program LINKMAP. LOD score calculations were
performed with a disease penetrance of either 0.75 and 0.90 and a
phenocopy rate of 0.001. Allele frequencies were assessed in a
population of unrelated individuals.
Titin Sequence Analyses
The genomic organization of the cardiac-specific N2-B region of
titin was determined as follows: Oligonucleotide
primers 12242 F (5'-GCCGGGCTTTGCAAGCAGCCGTGG-3') and 12589 R
(5'-GGAAGACACTTGGACTTTTTCTTA-3') generated from the titin cDNA sequence
(accession No. X9056814 ) were used to isolate BAC clone
211P22 (Genome Systems). BamHI/XbaI restriction
fragments of 211P22 were subcloned into Bluescript, and
nucleotide sequences were determined. Intron/exon
boundaries of the N2-B domain of titin were deduced from comparison of
genomic and cDNA sequences. The 2 exons encoding the N2-B domain were
amplified from patient DNA and sequenced using an ABI automated DNA
sequencer and the following primer pairs: 10355 (intron) F,
ATAAAGCAGAAGAAGGCCATCAAC; 11192 R, TCAGGAGCCTCTGGTGTGGACTTT; 11451 F,
CAGTATTCACTTTCAGCCTCTCAA; 13135 (intron) R, CAGGGCAGTAAGGGAAAAGGTGAG;
10434 F, ACTTGAACTTTTGTCTGAATCTCC; and 11940 R,
TTCTGTGC-ATGAGTGTTCTGAAGG.
| Results |
|---|
|
|
|---|
|
|
Four individuals were assigned an indeterminate disease status: 3 are children (IV-3, IV-6, and IV-9) with normal ventricular function, and 1 is an adult (III-5) with normal ventricular dimensions but reduced fractional shortening (27%).
Genetic Studies
Pedigree analyses indicated that the dilated
cardiomyopathy found in family MAO was transmitted
as an autosomal dominant trait that was expressed with incomplete
penetrance. To identify the chromosome location of this disease gene,
polymorphic loci throughout the genome were studied.
Analyses of 290 polymorphic loci excluded >70% of the
genome. Linkage between the dilated cardiomyopathy
in family MAO was found with locus D2S1244 (LOD score=4.86
at
=0). These data and genotypes at flanking loci (Table 2
) indicated a likelihood of >30 000:1
that the disease gene was located on chromosome 2q31. Multipoint
linkage analysis using data from loci D2S2157,
D2S346, and D2S324 demonstrated that the maximum
LOD scores achieved were robust to variations in penetrance and
allele frequency (Figure 2
and data
not shown).
|
|
A disease haplotype (Figure 1
) based on data from 6 loci was
identified in all affected individuals and obligate carriers (II-5 and
II-8). One other clinically unaffected adult also carried the entire
disease haplotype (individual II-6); 3 adults carried a portion of this
haplotype (individuals II-4, II-7, and IV-3).
Candidate Gene Analysis
The titin gene has been mapped to YACs 764H11, 930H10, 955D4, and
963D11, each of which is contained within the disease interval. Because
titin is a critical component of the cytoskeleton of cardiac and
skeletal myocytes, the massive gene encoding this protein was
considered a candidate for mutations that caused dilated
cardiomyopathy in family MAO. To screen for
disease-causing mutations, the cardiac-specific region of titin, N2-B,
was analyzed. A BAC clone (211P22; Genome Systems) containing
the N2-B region was isolated, its nucleotide sequence was
determined, and the genomic organization was deduced by comparison with
titin cDNA sequences.14 The N2-B domain is encoded in 2
exons of 2781 and 279 bp (designated exons A and B in Figure 3
). Sequence comparison of the N2-B
region in DNA samples derived from 2 affected and unaffected members of
family MAO revealed no disease-causing mutations in exon A or B (data
not shown). Five sequence variants were identified in exon A; 3 did not
alter the encoded amino acids, whereas 2 sequences predicted the
substitution of a threonine to a proline and a leucine to a
phenylalanine. These latter 2 sequence variants create novel
restriction enzyme sites that were identified in family MAO individuals
and unrelated, unaffected individuals (data not shown). We conclude
that neither are disease-causing mutations.
|
| Discussion |
|---|
|
|
|---|
To date, 6 different familial dilated
cardiomyopathy genes have been mapped, but only 1
disease gene, actin,10 has been defined. Although it is
possible that each of these disease loci encodes proteins that
participate in related processes, several lines of investigation
indicate that different mutations are likely to perturb distinct
pathways. Aberrant myocyte signaling cascades are potential etiologies,
given the altered expression of ß-adrenergic receptors in patients
with heart failure15 and the
cardiomyopathic phenotype of transgenic mice
expressing an activated
subunit of G
protein.16 Defects in the components of the myocyte
cytoskeleton are another likely cause of this disorder: actin mutations
cause familial dilated
cardiomyopathy,10 and targeted
disruption of genes encoding cytoskeletal proteins
-sarcoglycan17 or muscle LIM18 result in a
similar phenotype in mice.
On the basis of these data, 2 cytoskeletal genes (encoding nebulin and titin), located in the CMD1GI disease interval, were initially considered to be candidates for disease-causing mutations. Because the muscle protein nebulin has not been found in the heart,19 it was excluded from further analyses. The protein titin remained an excellent candidate given its role in specifying sarcomere length during myofibrillogenesis,17 18 contributions to passive tension generation,20 and altered expression in failing human hearts.21 Analyses of titin exons encoding the cardiac-specific domain, N2-B, failed to demonstrate a disease-causing mutation. Although a mutation in other regions of this massive (3 MDa) sarcomere protein has not been excluded, a defect located in titin domains that are expressed in all muscles would most likely cause both skeletal and cardiac muscle dysfunction. Based on the cardiac-restricted phenotype found in our study family, we therefore hypothesize that the likelihood of a disease-causing mutation elsewhere in titin sequences is low.
Eventual identification of the gene defect at CMD1G1 and other dilated cardiomyopathy loci should improve diagnosis of this heterogeneous disorder. Recognition of the clinical profile associated with each of these may help to guide management and improve survival of patients with dilated cardiomyopathy.
| Acknowledgments |
|---|
Received July 9, 1998; revision received November 2, 1998; accepted November 18, 1998.
| References |
|---|
|
|
|---|
2. Valentine HA, Hunt SA, Fowler MB, Billingham ME, Schroeder JS. Frequency of familial nature of dilated cardiomyopathy and usefulness of cardiac transplantation in this subset. Am J Cardiol. 1979;63:959963.
3.
Grunig E, Tasman JA, Kucherer H, Franz W, Kubler W,
Katus HA. Frequency and phenotypes of familial dilated
cardiomyopathy. J Am Coll Cardiol. 1998;31:186194.
4. Kass S, MacRae C, Graber HL, Sparks EA, McNamara D, Boudoulas H, Basson CT, Baker PB III, Cody RJ, Fishman MC, Cox N, Kong A, Wooley CF, Seidman JG, Seidman CE. A genetic defect that causes conduction system disease and dilated cardiomyopathy maps to 1p11q1. Nat Genet. 1994;7:546551.[Medline] [Order article via Infotrieve]
5. Olson TM, Keating MT. Mapping a cardiomyopathy locus to chromosome 3p22p25. J Clin Invest. 1996;97:528532.[Medline] [Order article via Infotrieve]
6. Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Linkage of familial dilated cardiomyopathy with conduction defects and muscular dystrophy to chromosome 6q23. Am J Human Genet. 1997;61:909917.[Medline] [Order article via Infotrieve]
7. Durand JB, Bachinski LL, Bieling LC, Czernuszewicz GZ, Abchee AB, Yu QT, Tapscott T, Hill R, Ifegwu J, Marian AJ, Brugada R, Daiger S, Gregoritch JM, Anderson J, Quinones M, Towbin JA, Roberts R. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation. 1995;92:33843389.
8. Krajinovic M, Pinamonti B, Sinagra G, Vatta M, Severini GM, Milasin J, Falaschi A, Camerini F, Giacca M, Mestroni L. Linkage of familial dilated cardiomyopathy to chromosome 9. Am J Hum Genet. 1995;57:846852.[Medline] [Order article via Infotrieve]
9. Bowles KR, Gajarski R, Porter P, Goytia V, Bachinski LL, Roberts R, Pignatelli R, Towbin JA. Gene mapping and autosomal dominant familial dilated cardiomyopathy to chromosome 10q2123. J Clin Invest. 1996;98:13551360.[Medline] [Order article via Infotrieve]
10. Olson TM, Michels VV, Thibodeau SN, Tai Y, Keating MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science. 1998;280:751752.
11. Brandenburg RO, Chazov E, Cherian G, Falase AO, Martin J, Orinius E, Goodwin JF, Olsen EGJ, Oakley CM, Pisa, Z. Report of the WHO/ISFC Task Force on the Definition and Classification of Cardiomyopathy. Circulation. 1981;64:437A438A.
12. Monolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD. Prevalence of etiology of idiopathic dilated cardiomyopathy (summary of National Heart, Lung, and Blood Institute Workshop). Am J Cardiol. 1992;69:14581466.[Medline] [Order article via Infotrieve]
13. Watkins H, MacRae C, Thierfelder L, Chou YH, Frenneaux M, McKenna W, Seidman JG, Seidman CE. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet. 1993;3:333336.[Medline] [Order article via Infotrieve]
14.
Labeit S, Kolmerer B. Titins, giant proteins in charge
of muscle ultrastructure and elasticity. Science. 1995;270:293296.
15. Bristow MR, Minobe WA, Raynolds MV, Port MD, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. Reduced ß1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993;92:27372745.
16.
D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA,
Dorn GWII. Transgenic G
q overexpression induces cardiac
contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94:81218126.
17.
Sakamoto A, Ono K, Abe M, Jasmin G, Eki T Murakami Y,
Masaki T, Yoyo-oka T, Hanaoka F. Both hypertrophic and dilated
cardiomyopathy are caused by mutation of the same
gene,
sarcoglycan, in hamster: an animal model of disrupted
dystrophin-associated glycoprotein complex. Proc Natl
Acad Sci U S A. 1997;94:1387313878.
18. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy and heart failure. Cell. 1997;88:393403.[Medline] [Order article via Infotrieve]
19.
Schiaffino S, Reggiani C. Molecular diversity of
myofibrillar proteins: gene regulation and functional significance.
Physiol Rev. 1996;76:371423.
20.
Helmes M, Trombitas K, Granzier H. Titin develops
restoring force in rat cardiac myocytes. Circ Res. 1996;79:619626.
21. Hein S, Scholz D, Fujitani N, Rennollet H, Brand T, Friedl A, Schaper J. Altered expression of titin and contractile proteins in failing human myocardium. J Mol Cell Cardiol. 1994;26:12911306.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
A. Kontrogianni-Konstantopoulos, M. A. Ackermann, A. L. Bowman, S. V. Yap, and R. J. Bloch Muscle Giants: Molecular Scaffolds in Sarcomerogenesis Physiol Rev, October 1, 2009; 89(4): 1217 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Linke Sense and stretchability: The role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction Cardiovasc Res, March 1, 2008; 77(4): 637 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hoshijima, R. Knoll, M. Pashmforoush, and K. R. Chien Reversal of Calcium Cycling Defects in Advanced Heart Failure: Toward Molecular Therapy J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A15 - A23. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Mahon, R. T. Murphy, C. A. MacRae, A. L.P. Caforio, P. M. Elliott, and W. J. McKenna Echocardiographic Evaluation in Asymptomatic Relatives of Patients with Dilated Cardiomyopathy Reveals Preclinical Disease Ann Intern Med, July 19, 2005; 143(2): 108 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Udd, A. Vihola, J. Sarparanta, I. Richard, and P. Hackman Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J Neurology, February 22, 2005; 64(4): 636 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Beery, M. Dyment, K. Shooner, T. K. Knilans, and D. W. Benson A Candidate Locus Approach Identifies a Long QT Syndrome Gene Mutation Biol Res Nurs, October 1, 2003; 5(2): 97 - 104. [Abstract] [PDF] |
||||
![]() |
P. A. Doevendans Genetic Polymorphisms and Cardiac Failure Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 23 - 29. [PDF] |
||||
![]() |
M. Gotthardt, R. E. Hammer, N. Hubner, J. Monti, C. C. Witt, M. McNabb, J. A. Richardson, H. Granzier, S. Labeit, and J. Herz Conditional Expression of Mutant M-line Titins Results in Cardiomyopathy with Altered Sarcomere Structure J. Biol. Chem., February 14, 2003; 278(8): 6059 - 6065. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fatkin and R. M. Graham Molecular Mechanisms of Inherited Cardiomyopathies Physiol Rev, October 1, 2002; 82(4): 945 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, S. P. Bell, K. Trombitas, C. C. Witt, S. Labeit, M. M. LeWinter, and H. Granzier Changes in Titin Isoform Expression in Pacing-Induced Cardiac Failure Give Rise to Increased Passive Muscle Stiffness Circulation, September 10, 2002; 106(11): 1384 - 1389. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Rankinen, P. An, L. Perusse, T. Rice, Y. C. Chagnon, J. Gagnon, A. S. Leon, J. S. Skinner, J. H. Wilmore, D. C. Rao, et al. Genome-wide linkage scan for exercise stroke volume and cardiac output in the HERITAGE Family Study Physiol Genomics, August 14, 2002; 10(2): 57 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Mahon, B. P. Madden, A. L. P. Caforio, P. M. Elliott, A. J. Haven, B. E. Keogh, M. J. Davies, and W. J. McKenna Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy J. Am. Coll. Cardiol., February 6, 2002; 39(3): 455 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Haravuori, A. Vihola, V. Straub, M. Auranen, I. Richard, S. Marchand, T. Voit, S. Labeit, H. Somer, L. Peltonen, et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: Titin is the candidate gene Neurology, April 10, 2001; 56(7): 869 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gavazzi, A. Repetto, L. Scelsi, C. Inserra, M.L. Laudisa, C. Campana, C. Specchia, B. Dal Bello, M. Diegoli, L. Tavazzi, et al. Evidence-based diagnosis of familial non-X-linked dilated cardiomyopathy. Prevalence, inheritance and characteristics Eur. Heart J., January 1, 2001; 22(1): 73 - 81. [Abstract] [PDF] |
||||
![]() |
M. Kamisago, S. D. Sharma, S. R. DePalma, S. Solomon, P. Sharma, B. McDonough, L. Smoot, M. P. Mullen, P. K. Woolf, E. D. Wigle, et al. Mutations in Sarcomere Protein Genes as a Cause of Dilated Cardiomyopathy N. Engl. J. Med., December 7, 2000; 343(23): 1688 - 1696. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Arbustini, P. Morbini, A. Pilotto, A. Gavazzi, and L. Tavazzi Familial dilated cardiomyopathy: from clinical presentation to molecular genetics Eur. Heart J., November 2, 2000; 21(22): 1825 - 1832. [PDF] |
||||
![]() |
F Tesson, N Sylvius, A Pilotto, L Dubosq-Bidot, M Peuchmaurd, C Bouchier, A Benaiche, L Mangin, P Charron, A Gavazzi, et al. Epidemiology of desmin and cardiac actin gene mutations in a European population of dilated cardiomyopathy Eur. Heart J., November 2, 2000; 21(22): 1872 - 1876. [Abstract] [PDF] |
||||
![]() |
J. Schonberger, H. Levy, E. Grunig, S. Sangwatanaroj, D. Fatkin, C. MacRae, H. Stacker, C. Halpin, R. Eavey, E. F. Philbin, et al. Dilated Cardiomyopathy and Sensorineural Hearing Loss : A Heritable Syndrome That Maps to 6q23-24 Circulation, April 18, 2000; 101(15): 1812 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Sussman, S. Welch, A. Walker, R. Klevitsky, T. E. Hewett, S. A. Witt, T. R. Kimball, R. Price, H. W. Lim, and J. D. Molkentin Hypertrophic defect unmasked by calcineurin expression in asymptomatic tropomodulin overexpressing transgenic mice Cardiovasc Res, April 1, 2000; 46(1): 90 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fatkin, C. MacRae, T. Sasaki, M. R. Wolff, M. Porcu, M. Frenneaux, J. Atherton, H. J. Vidaillet, S. Spudich, U. De Girolami, et al. Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System Disease N. Engl. J. Med., December 2, 1999; 341(23): 1715 - 1724. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mestroni, C. Rocco, D. Gregori, G. Sinagra, A. Di Lenarda, S. Miocic, M. Vatta, B. Pinamonti, F. Muntoni, A. L. P. Caforio, et al. Familial dilated cardiomyopathy: Evidence for genetic and phenotypic heterogeneity J. Am. Coll. Cardiol., July 1, 1999; 34(1): 181 - 190. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-L. Bang, T. Centner, F. Fornoff, A. J. Geach, M. Gotthardt, M. McNabb, C. C. Witt, D. Labeit, C. C. Gregorio, H. Granzier, et al. The Complete Gene Sequence of Titin, Expression of an Unusual {approx}700-kDa Titin Isoform, and Its Interaction With Obscurin Identify a Novel Z-Line to I-Band Linking System Circ. Res., November 23, 2001; 89(11): 1065 - 1072. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |